Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

60 Degrees Pharmaceuticals Fast Tracked For Malaria Drug

By 60 Degrees Pharmaceuticals | January 5, 2018

60 Degrees Pharmaceuticals (60P) has received Fast Track designation from the Food and Drug Administration (FDA) for the investigation of Tafenoquine for prevention of malaria in adults.

A drug is designated as a fast track product “for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition,”1 according to the FDA.

In December, 60P submitted a New Drug Application (NDA) to the FDA for the use of Tafenoquine to prevent malaria in adults traveling to areas where the disease is prevalent.

Malaria, a life-threatening disease transmitted through the bite of an infected mosquito, caused an estimated 429,000 fatalities and 212 million clinical cases in 2015.2 It poses a significant risk to millions of healthy individuals traveling in many parts of the world, including employees of non-governmental organizations, casual vacationers, industrial and business workers, and military forces.3

Malaria cases among travelers returning to the U.S. have been trending upwards, with 84 percent of those infected requiring hospitalization.4

“Finding acceptable drugs to safeguard travelers and deployed military personnel against malaria is a real problem,” said Geoffrey Dow, Ph.D., CEO 60 Degrees Pharmaceuticals. We see Fast Track Designation as a next step toward marketing this product with a convenient weekly dosing regimen in the United States, and eventually around the world. It is our continued belief our dossier will receive priority review, thereby expediting the review of Tafenoquine.”

60P entered into a cooperative research and development agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA) in 2014 to develop Tafenoquine as a weekly prophylactic drug for the prevention of malaria.

Since malaria is the top infectious disease threat to U.S. Military service members overseas, the military maintains a robust anti-malarial drug development effort through internal research and commercial partnerships.

A recent analysis of five clinical trials to assess the safety and tolerability of Tafenoquine has been published in Travel Medicine and Infectious Disease, a peer reviewed journal. The authors concluded that Tafenoquine appeared to be safe and well tolerated when the anticipated clinical regimen (ACR) was administered.

In all five studies, the majority of adverse events were mild or considered unrelated to the study drug.

See the full article: “Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis,” by Moreno et al., 2017.
_______________________________________________________

References:

1 Guidance for Industry, Expedited Programs for Serious Conditions-Drugs and Biologics, U.S. Department of Health and Human Services Food and Drug Administration, May 2014, https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf

2 CDC. 2017. Malaria Facts.

3 WWARN. 2017. Antimalarial Drug Resistance https://www.wwarn.org/about-us/malaria-drug-resistance

4 Cullen KA, Mace KE, Arguin PM. Malaria Surveillance-United States, 2013 MMWR Surveillance Summary 2016:65 (No.SS-2);1-22 DOI: https://dx.doi.org/10.15585/mmwr.SS6502a1

(Source: 60 Degrees Pharmaceuticals)


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE